<!DOCTYPE html>
<html lang="en" dir="ltr">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <link rel="manifest" href="/manifest.json">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">

  <title>Anal Cancer: Information & Treatment | StopMyCancer</title>
  <meta name="description" content="Understanding anal cancer. HPV risks, squamous cell carcinoma, diagnosis, chemoradiation, and surgery options.">
  <meta name="keywords" content="anal cancer, squamous cell carcinoma, HPV, Nigro protocol, chemoradiation, Mitomycin C, 5-FU, abdominoperineal resection">
  <meta name="author" content="StopMyCancer">
  <link rel="canonical" href="https://stopmycancer.com/cancers/anal/">

  <meta property="og:type" content="article">
  <meta property="og:title" content="Anal Cancer: Information & Treatment">
  <meta property="og:description" content="Comprehensive guide to anal cancer, HPV, chemoradiation, and treatment options.">
  <meta property="og:url" content="https://stopmycancer.com/cancers/anal/">
  <meta property="og:site_name" content="StopMyCancer">
  <meta property="og:locale" content="en_US">

  <link rel="preconnect" href="https://fonts.googleapis.com">
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
  <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700;800&display=swap" rel="stylesheet">
  <link rel="stylesheet" href="/css/styles.css">
  <link rel="icon" type="image/svg+xml" href="data:image/svg+xml,<svg xmlns='http://www.w3.org/2000/svg' viewBox='0 0 100 100'><text y='.9em' font-size='90'>üõ°Ô∏è</text></svg>">
</head>
<body>

  <a href="#main" class="skip-link">Skip to main content</a>

  <header class="header" role="banner">
    <div class="header__inner">
      <a href="/" class="header__logo" aria-label="StopMyCancer Home">
        <div class="header__logo-icon" aria-hidden="true">S</div>
        Stop<span>My</span>Cancer
      </a>

      <nav class="header__nav" role="navigation" aria-label="Main navigation">
        <a href="/cancers/" class="header__nav-link">Cancer Types</a>
        <a href="/navigate/" class="header__nav-link">Navigate</a>
        <a href="/stories/" class="header__nav-link">Stories</a>
        <a href="/access/" class="header__nav-link">Access &amp; Equity</a>
        <a href="/tools/pathology-translator" class="header__nav-link">Translator Tool</a>
        <a href="/about/" class="header__nav-link">About</a>
      </nav>

      <div class="header__actions">
        <div class="lang-switcher">
          <button class="lang-switcher__btn" aria-haspopup="true" aria-expanded="false" aria-label="Change language">
            <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><circle cx="12" cy="12" r="10"></circle><line x1="2" y1="12" x2="22" y2="12"></line><path d="M12 2a15.3 15.3 0 0 1 4 10 15.3 15.3 0 0 1-4 10 15.3 15.3 0 0 1-4-10 15.3 15.3 0 0 1 4-10z"></path></svg>
            EN
            <svg width="12" height="12" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><path d="M6 9l6 6 6-6"></path></svg>
          </button>
          <div class="lang-switcher__dropdown" role="menu">
            <a href="/cancers/anal/" class="lang-switcher__option lang-switcher__option--active" role="menuitem">English</a>
          </div>
        </div>

        <button class="mobile-toggle" aria-label="Open menu" aria-expanded="false" aria-controls="mobile-nav">
          <span class="mobile-toggle__line"></span>
          <span class="mobile-toggle__line"></span>
          <span class="mobile-toggle__line"></span>
        </button>
      </div>
    </div>
  </header>

  <nav class="mobile-nav" id="mobile-nav" role="navigation" aria-label="Mobile navigation">
    <a href="/cancers/" class="mobile-nav__link">Cancer Types</a>
    <a href="/navigate/" class="mobile-nav__link">Navigate</a>
    <a href="/stories/" class="mobile-nav__link">Stories</a>
    <a href="/access/" class="mobile-nav__link">Access &amp; Equity</a>
    <a href="/tools/pathology-translator" class="mobile-nav__link">Pathology Translator</a>
    <a href="/about/" class="mobile-nav__link">About</a>
  </nav>

  <main id="main">

    <section class="page-header">
      <div class="container">
        <div class="breadcrumbs" role="navigation" aria-label="Breadcrumbs">
          <a href="/">Home</a> <span aria-hidden="true">/</span> <a href="/cancers/">Cancer Types</a> <span aria-hidden="true">/</span> <span>Anal Cancer</span>
        </div>
        <h1>Anal Cancer</h1>
        <p class="page-header__subtitle">Understanding anal cancer. HPV risks, diagnosis, and chemoradiation-based treatment approaches.</p>
      </div>
    </section>

    <section class="main-content">
      <div class="container">
        <div class="grid grid--content-sidebar">

          <article class="article">

            <section class="summary">
              <p><strong>Anal cancer is a rare malignancy usually caused by HPV infection.</strong> Most cases are squamous cell carcinoma. Unlike colorectal cancer, the standard treatment is chemoradiation (not surgery first), which preserves sphincter function and continence. Cure rates are good with multimodal treatment.</p>
            </section>

            <section>
              <h2>What Is Anal Cancer?</h2>
              <p>Anal cancer develops at the junction where the rectum meets the anus. Most are squamous cell carcinomas. The disease is highly associated with HPV infection (similar to cervical cancer).</p>
              <p><strong>Key fact:</strong> Unlike colorectal cancer, chemoradiation (not surgery) is the primary treatment, allowing preservation of normal sphincter function and continence in most patients.</p>
            </section>

            <section>
              <h2>Risk Factors</h2>
              <ul>
                <li><strong>HPV infection:</strong> Most important risk factor. HPV-16 and HPV-18 strongly associated. Vaccination prevents anal cancer.</li>
                <li><strong>Receptive anal intercourse:</strong> Increases HPV transmission risk.</li>
                <li><strong>Immunosuppression:</strong> HIV+ individuals have higher risk, especially with low CD4 counts.</li>
                <li><strong>History of cervical or vulvar cancer:</strong> In women with HPV-related cancers, anal cancer risk increased.</li>
                <li><strong>Smoking:</strong> Increases risk and may worsen chemoradiation toxicity.</li>
              </ul>
            </section>

            <section>
              <h2>Symptoms</h2>
              <ul>
                <li>Rectal bleeding or bloody stools</li>
                <li>Anal pain or pressure</li>
                <li>Anal mass or lump (noted by patient)</li>
                <li>Anal itching</li>
                <li>Change in bowel habits</li>
                <li>Enlarged lymph nodes in groin or abdomen</li>
              </ul>
              <p><strong>Important:</strong> Many patients with anal symptoms avoid seeking care due to embarrassment. Any persistent anal symptoms warrant medical evaluation.</p>
            </section>

            <section>
              <h2>Diagnosis</h2>
              <p><strong>Diagnostic approach:</strong></p>
              <ul>
                <li><strong>Digital rectal exam (DRE):</strong> First step; palpates for mass.</li>
                <li><strong>Anoscopy:</strong> Direct visualization with biopsy for pathologic confirmation.</li>
                <li><strong>HPV testing:</strong> Identifies HPV status; prognostic value.</li>
                <li><strong>Staging imaging:</strong> CT or MRI pelvis (local extent), CT chest (distant metastases).</li>
                <li><strong>PET scan:</strong> May help identify metastatic disease.</li>
              </ul>
            </section>

            <section>
              <h2>Staging</h2>
              <p>Uses TNM system. Tumors are typically classified by:</p>
              <ul>
                <li><strong>T:</strong> Tumor size and extent (T1: &lt;2cm, T2: 2-5cm, T3: &gt;5cm, T4: invasion of adjacent structures)</li>
                <li><strong>N:</strong> Lymph node involvement (N0, N1, N2, N3 based on location and number)</li>
                <li><strong>M:</strong> Distant metastases (M0 vs M1)</li>
              </ul>
            </section>

            <section>
              <h2>Treatment Options</h2>

              <h3>Chemoradiation (Standard Treatment)</h3>
              <p><strong>Nigro protocol</strong> (named after its developer) is the gold standard:</p>
              <ul>
                <li><strong>Chemotherapy:</strong> Mitomycin C (single dose week 1) + 5-FU (continuous infusion for 4-5 weeks)</li>
                <li><strong>Radiation:</strong> 45-54 Gy external beam radiation over 5-6 weeks to primary tumor and regional nodes</li>
              </ul>
              <p>Cure rates: 80-90% for localized disease without surgery.</p>

              <h3>Surgery</h3>
              <p><strong>Reserved for:</strong></p>
              <ul>
                <li>Residual disease after chemoradiation (salvage abdominoperineal resection/APR)</li>
                <li>Recurrent disease</li>
                <li>Poor performance status unable to tolerate chemoradiation</li>
              </ul>
              <p>APR involves removal of rectum and anus with permanent colostomy.</p>

              <h3>Surveillance After Chemoradiation</h3>
              <p>Most patients achieve complete response and are cured. Surveillance includes clinical exam, imaging, and assessment for late toxicity.</p>
            </section>

            <section>
              <h2>Side Effects &amp; Toxicity</h2>
              <p><strong>Acute side effects (during chemoradiation):</strong></p>
              <ul>
                <li>Severe dermatitis (skin irritation in irradiated area)</li>
                <li>Diarrhea and proctitis (inflammation of rectum)</li>
                <li>Anal pain</li>
                <li>Nausea and myelosuppression (from chemotherapy)</li>
              </ul>
              <p><strong>Late side effects (months to years after):</strong></p>
              <ul>
                <li>Chronic diarrhea or constipation</li>
                <li>Fecal incontinence (usually minor)</li>
                <li>Sexual dysfunction</li>
                <li>Stenosis (narrowing) of anus or rectum (rare)</li>
              </ul>
              <p><strong>Management:</strong> Most side effects managed supportively. Smoking cessation improves outcomes and reduces toxicity.</p>
            </section>

            <section>
              <h2>Prognosis</h2>
              <p>Excellent with chemoradiation:</p>
              <ul>
                <li><strong>Early-stage (T1-2, N0):</strong> 80-90% 5-year survival.</li>
                <li><strong>Locally advanced (T3-4 or N+):</strong> 60-75% 5-year survival.</li>
                <li><strong>Metastatic:</strong> Palliative chemotherapy; median survival 12-18 months.</li>
              </ul>
              <p>HPV status may affect prognosis, with HPV-positive disease potentially having better outcomes.</p>
            </section>

            <section class="urgent-box">
              <h2>Seek Immediate Care If You Experience:</h2>
              <ul>
                <li>Severe rectal bleeding</li>
                <li>Severe anal pain or inability to sit</li>
                <li>Signs of fecal impaction or complete obstruction</li>
              </ul>
            </section>

            <section>
              <h2>Key Questions for Your Doctor</h2>
              <ul>
                <li>What is my stage?</li>
                <li>What is my HPV status?</li>
                <li>Am I a candidate for standard chemoradiation?</li>
                <li>What are specific side effects I should expect?</li>
                <li>How is response to treatment monitored?</li>
                <li>What happens if there is residual disease after chemoradiation?</li>
                <li>Are there clinical trials for anal cancer?</li>
              </ul>
            </section>

          </article>

        </div>
      </div>
    </section>

  </main>

  <footer class="footer">
    <div class="container">
      <div class="footer__content">
        <div class="footer__section">
          <h3>StopMyCancer</h3>
          <p>Your cancer. Explained. Supported. Navigated.</p>
        </div>
        <div class="footer__section">
          <h4>Navigation</h4>
          <ul>
            <li><a href="/cancers/">Cancer Types</a></li>
            <li><a href="/navigate/">Navigate</a></li>
            <li><a href="/stories/">Stories</a></li>
            <li><a href="/access/">Access &amp; Equity</a></li>
          </ul>
        </div>
        <div class="footer__section">
          <h4>Resources</h4>
          <ul>
            <li><a href="/tools/pathology-translator">Pathology Translator</a></li>
            <li><a href="/about/">About</a></li>
            <li><a href="https://github.com/fantravel1/stopmycancer" target="_blank">GitHub</a></li>
          </ul>
        </div>
      </div>
      <div class="footer__bottom">
        <p>&copy; 2025 StopMyCancer. Licensed under CC BY 4.0.</p>
      </div>
    </div>
  </footer>

  <script src="/js/main.js"></script>

</body>
</html>
